Moreover, treatment of low metastatic human ovarian cancer cells (OVCAR-3) with the OGA inhibitors Thiamet-G and PUGNAc enhances their migration potential and decreases the expression of E-cadherin, consequently blocking the formation of the E-cadherin/catenin complex reducing intracellular adhesion. The gene discussed is CDH1; the disease is ovarian carcinoma.